RAPT Therapeutics (RAPT) director Gray received 4,956 shares
Insider transactions reported
Mary Ann Gray (director at RAPT Therapeutics Inc., RAPT) reported that they received 4,956 shares on Jan 30, 2026. After these transactions the filing shows 4,956 shares held directly.
- Reporting person
- Gray Mary Ann
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 30, 2026 | Grant or award (A) | Common Stock1 | +4,956 | - | - | 4,956 direct |
Holdings before and after
- Common Stock: 0 to 4,956 direct
Footnotes from the filing
- 1. Represents the annual grant of restricted stock units ( RSUs ) under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Gray report in this RAPT Form 4?
Mary Ann Gray (director at RAPT Therapeutics Inc., RAPT) reported that they received 4,956 shares on Jan 30, 2026. After these transactions the filing shows 4,956 shares held directly.
How many RAPT shares does Gray hold after this filing?
The filing shows 4,956 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for RAPT
Across the 7 sessions after earlier RAPT headlines, the stock closed higher 4 times and lower 3 times, with a median move of 3.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RAPT | SPY |
|---|---|---|---|
| Jan 9, 2026 | Piper Sandler initiated coverage on RAPT Therapeutics with a new price target | +7.8% | +0.7% |
| Jan 8, 2026 | RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | -3.8% | -0.0% |
| Nov 6, 2025 | RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | +2.7% | -1.1% |
| Nov 5, 2025 | RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences | -0.8% | +0.3% |
| Oct 27, 2025 | Guggenheim initiated coverage on RAPT Therapeutics with a new price targetand 1 other headline that session | +1.9% | +1.2% |
| Oct 22, 2025 | RAPT Therapeutics Announces Pricing of Public Offering of Common Stockand 1 other headline that session | -10.5% | -0.5% |
Earlier insider filings at RAPT
- Feb 2, 2026Director Lyons-Williams Lori was granted 4,956 shares (SEC Form 4)
- Feb 2, 2026Director Kozick Linda was granted 4,956 shares (SEC Form 4)
- Feb 2, 2026Director Dombkowski Ashley L. was granted 4,956 shares (SEC Form 4)
- Jul 1, 2025SEC Form 4 filed by Director Dombkowski Ashley L.
- Jun 24, 2025SEC Form 4 filed by Director Braunstein Scott
Keep researching RAPT
- RAPT insider tradesEvery buy and sale reported by RAPT Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2019
Follow RAPT and get a push notification the moment its next story breaks.